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Background:Multiple functions have been ascribed to NLRC5 including MHC-I transcription and cytokine responses.
Results:We generatedNlrc5/ mice and showed that Nlrc5 increases classical and nonclassicalMHC-I and causes removal of
the gene-silencing H3K27me3 histone modification on MHC-I promoter.
Conclusion: Nlrc5 regulates MHC-I expression.
Significance: NLRC5, with CIITA, constitutes an NLR subfamily that regulates MHC.
Most of the nucleotide-binding domain, leucine-rich repeat
(NLR) proteins regulate responses to microbial and damage-as-
sociated products. Class II transactivator (CIITA) has a distinct
function as the master regulator of class II major histocompati-
bility complex (MHC-II) transcription. Recently, human
NLRC5 was found to regulate MHC-I in cell lines; however, a
host of conflicting positive and negative functions has been
attributed to this protein. To address the function ofNLRC5 in a
physiologic setting, we generated an Nlrc5/ strain that con-
tains a deletion in the exon that encodes the nucleotide-binding
domain.We have not detected a role for this protein in cytokine
induction by pathogen-associated molecular patterns and
viruses. However,Nlrc5/ cells showed a dramatic decrease of
classical (H-2K) and nonclassical (Tla) MHC-I expression by
T/B lymphocytes, natural killer (NK) cells, and myeloid-mono-
cytic lineages. As a comparison, CIITA did not affect mouse
MHC-I expression.Nlrc5/ splenocytes and bone marrow-de-
rivedmacrophages were able to up-regulateMHC-I in response
to IFN-; however, the absolute levels of MHC-I expression
were significantly lower than WT controls. Chromatin immu-
noprecipitation of IFN--treated cells indicates that Nlrc5
reduced the silencing H3K27me3 histone modification, but did
not affect the activating AcH3 modification on a MHC-I pro-
moter. In summary, we conclude that Nlrc5 is important in the
regulation of MHC-I expression by reducing H3K27me3 on
MHC-I promoter and joins CIITA as an NLR subfamily that
controls MHC gene transcription.
NLR3 proteins conduct a variety of functions, including
inflammasome-associated function, NF-B/MAPK activation,
interferon (IFN) regulation, cell death, and autophagy (1).
These functions are primarily elicited in response to pathogen-
associatedmolecular patterns (PAMPs) or damaged-associated
molecular patterns (DAMPs). In contrast, the class II transac-
tivator (CIITA) has remained the only NLR that has been veri-
fied in both human and mice as a master transactivator of all
major histocompatibility II (MHC-II) genes as well as genes
encoding their accessory proteins, such as the invariant chain
and H-2DM proteins (2). CIITA is shown to conduct its func-
tion by association with the DNA-binding proteins, NF-Y and
Regulatory Factor X (RFX), which recognize their cognate
binding motifs, the X and Y elements that are conserved in all
MHC-II promoters (3, 4). The assembly of this enhanceosome
is necessary for the modification of MHC-II promoters via his-
tone acetylation and methylation. Additionally, CIITA inter-
acts with insulator factor, CCCTC binding factor (CTCF), to
assure against gene silencing (5).
In addition to the regulation ofMHC-II, CIITA was simulta-
neously found by our group and another laboratory to regulate
humanMHC-I (6, 7). Both groups showed thatmutant cell lines
with a defective CIITA protein have defective MHC-I expres-
sion and that wild type CIITA complemented this defect. Addi-
tionally, CIITA mediates MHC-I gene transactivation through
a regulatory DNA motif known as the  site in its promoter.
Subsequently, others have shown that CIITA activates MHC-I
uniquely in a TATA box binding protein (TBP)-associated fac-
tor-1-independent fashion (8).
Recently, human NLRC5 was found to positively regulate
MHC-I in cell lines (9, 10), although another group obtained
the opposite finding and concluded that NLRC5 reduced
MHC-I and CD40 expression (11). The former group overex-
pressed NLRC5 in Jurkat T cells and found that the expression
of class I MHC as well as B2M, Transporter associated with
antigen processing (TAP), and Large multifunctional protease
(LMP) was enhanced, whereas siRNA targeting NLRC5 caused
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the reduction of MHC-I. Similar to CIITA, they found that the
Walker A and B motifs common among ATP-binding proteins
are critical for both theMHC-I-inducing function of NLRC5 as
well as its nuclear translocation. Furthermore, overexpressed
NLRC5was detected onMHC-I promoter by chromatin immu-
noprecipitation (ChIP), suggesting a direct binding of NLRC5
to the MHC-I promoter.
NLRC5 is highly expressed by cells in the immune system, in
particular by cells of the lymphocytic and myeloid-monocytic
cell lineages (11–13). It can be found in the nucleus (9–11),
although cytoplasmic localization (10, 14) is also reported, and
an overexpressed NLRC5 has been shown to shuttle between
the nucleus and cytoplasm. Its expression is highly inducible by
IFN- and LPS (9, 11, 14), and IFN- andCMV inducedNLRC5
promoter activation via the Jak/Stat pathway (14).
However, a host of additional functional roles has been
attributed to this protein, although a caveat is that many of the
functional studies on NLRC5 have been limited to cell lines.
Two groups showed a negative regulatory function for NLRC5.
Cui et al. (15) demonstrated the interaction of endogenous
NLRC5 with endogenous IB kinases (IKK) / to reduce the
phosphorylation state of IKKs. They further showed that siRNA
directed at NLRC5 resulted in elevated TNF and IL-6 in
response to LPS in both human and mouse macrophage cell
lines. This group also found that gene knockdown resulted in
elevated antivesicular stomatitis virus response including
enhanced expression of type-I interferons. In agreement with
this, Benko et al. (11) showed an inhibitory effect of NLRC5
overexpression on NF-B-, AP-1-, and IFN-sensitive response
element reporter assays in the mouse macrophage line
RAW264, whereas knocking down the gene resulted in an
enhancement of IL-1, IL-6, TNF, CD40, and class I MHC in
response to LPS or IFN-. By contrast, two other groups
showed that NLRC5 positively regulates cytokine responses to
nucleic acids and viruses. Kuenzel et al. (14) used a forced
dimerization system involving the caspase recruitment domain
(CARD) domain of NLRC5 and found elevated gamma inter-
feron activation site (GAS)- and IFN-sensitive response ele-
ment-driven reporter activation. These authors further found
that NLRC5 overexpression moderately enhanced IFN- and
its downstream targets, OAS1 and P58 repressor protein kinase
(PRKRIR), whereas siRNA targetingNLRC5 reduced the IFN-
pathway in response to CMV. In agreement with these authors,
Neerincx et al. (13) found that siRNA targeting NLRC5 in pri-
mary human dermal fibroblasts caused a drop in IFN- and
Rantes (regulated on activation normal T cell expressed and
secreted) in response to poly(I:C) or Sendai virus.
Our group used a gene knockdown approach to show that
NLRC5 reduction resulted in the lack of inflammasome activa-
tion in THP-1 cells and in primary human peripheral blood
monocytic cells and further that NLRC5 can reconstitute an
inflammasome system (16). This result is supported by another
group that also found that overexpressed NLRC5 can reconsti-
tute an inflammasome (17). However, this same group pro-
duced anNlrc5/ mouse strain and found that inflammasome
activation, cytokine response to LPS and IFN-, type-I IFN and
cytokine responses to poly(I:C), RNA virus, stimulatory DNA,
andDNA viruses were all normal in this strain. Furthermore, in
vivo response to poly(I:C) was also normal in Nlrc5/ mice.
The composite results revealed a rather confusing picture
regarding the function of NLRC5, and the study of Nlrc5/
mice did not identify a positive function (17). To readdress the
function of NLRC5, we produced anNlrc5 gene deletionmouse
targeting the NBD-encoding exon. We observed a profound
effect of Nlrc5 deletion on MHC-I expression in lymphocytes
and NK cells and explored the effect of Nlrc5 on the histone
modification of an MHC-I promoter. The deletion of Nlrc5
resulted in a less dramatic reduction of MHC-I on B cells and
myeloid-monocytic cells, leading us to ask whether residual
CIITA might account for the differential effect of Nlrc5 on
T/NK, which do not express CIITA versus B cells that do
express CIITA. In addition, we also explored possible explana-
tions for the discrepant finding where others describe a role for
Nlrc5 in regulating cytokine production.
EXPERIMENTAL PROCEDURES
Animal Care and Use—C57BL/6J, Ciita/ (18), and
Nlrc5/ mice were bred in-house in accordance with the
National Institute of Health Guide for the Care and Use of Lab-
oratory Animals and the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
Generation of Nlrc5/ Mice—The Nlrc5/ NBD was
ablated as described in the legend for Fig. 1. Exons 3 and 4 were
replaced with the neomycin cassette, and the targeting vector
was confirmed by restriction digest analysis and sequencing.
The linearized vector was electroporated in IC1 (C57BL6/N)
embryonic stem cells (InGenious Targeting Laboratories).
Homologous recombinants were verified by Southern blot
analysis before injection into BALB/c blastocysts. The resulting
chimeras were mated to female C57BL/6J mice, and the result-
ing heterozygotes were crossed to yield homozygous Nlrc5/
mice, which were screened using duplex PCR with each reac-
tion containing the following primers: P1 WT NBD primer,
5-TAGAGTTGTATCACTGTGTGGCTGAGACCC-3; P2
Neo primer, 5-GGAACTTCGCTAGACTAGTACGCGTG-
3;P3 common primer, 5-TTTAGCTGATAGATACAGAGC-
CTTGGACC-3, yielding bands of 650 bp for WT and 330 bp
for Nlrc5 knock-out.
PrimaryCell Isolation—Single cell splenocyte and thymocyte
suspensions were made by gentle dissociation of tissues with a
1-ml syringe plunger over a 70-m strainer followed by red
blood cell lysis using ACK buffer (Invitrogen), and viable cells
were counted using Trypan blue staining and stimulated as
indicated. Peritoneal macrophages were isolated by seeding
peritoneal lavage cells in DMEM (Invitrogen)10% FCS-
(HyClone) at a density of 5  105 cells/well in 96-well plates.
After 16 h, the nonadherent cells were removed by washing
three times with PBS (Invitrogen), and the remaining adherent
cells were used for stimulation. Bone marrow-derived macro-
phages (BMDM) were generated as described previously (19).
All cultures were supplemented with 1 penicillin/streptomy-
cin (Sigma).
Viral Infection—BMDMwere seeded at 2  105 cells/well in
flat bottom 96-well plates and infected with herpes simplex
virus (HSV) (multiplicity of infection of 0.2, 1, and 10) or SeV
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(80 HA unit/ml). Supernatant was collected from triplicate
wells of virus ormock-infected cells and tested for IFN- secre-
tion by ELISA.
PAMP, DAMP, and Cytokine Stimulation—BMDM were
seeded at 2  105 cells/well in flat bottom 96-well plates and
were left untreated or stimulated for 8 h with 200 ng/ml Esch-
erichia coliK12 LPS (InvivoGen), 4 MCpG (InvivoGen), or 50
g/ml poly(I:C) (InvivoGen). Supernatant was collected for
ELISA, and cells were harvested for mRNA transcript analysis.
Inflammasome induction was mediated using an LPS prime of
200 ng/ml for 3 h followed by the addition of 400g/ml Imject
alum (Pierce) for 6 h or 2 mM ATP (InvivoGen) for 40 min.
IFN- stimulation of BMDM and splenocytes used 500
units/ml of recombinant murine IFN- (PeproTech) at the
indicated time points.
Flow Cytometry—The following reagents were used for flow
cytometric staining: CD3-FitC, CD19-eFluor-450, biotin-H2-
Kb, biotin-H2-Db, Avidin-APC, CD11c-PE-Cy5, and CD4-PE
(eBioscience); NK1.1-PE-Cy7 and CD8-Pacific Blue (Bio-
Legend); I-Ab-PE (Pharmingen); Live/Dead Aqua and Violet
(Molecular Probes); CD45-Pacific Orange (Invitrogen);
CD11b-PE (Beckman Coulter). All data were collected on
CyAnTM (Beckman Coulter) or LSRII (BD Biosciences), and
sorting was performed using MoFloTM or MoFloTM XDP
(Beckman Coulter). All data were analyzed using FlowJo
(TreeStar).
ELISA—Detection of murine TNF-, IL-6, and IL-1 was
performed using BD OptEIATM kits (BD Biosciences) accord-
ing to themanufacturer’s instructions. IFN-ELISAutilizes the
following reagents: 4g/ml rat anti-mouse IFN- capture anti-
body(Yamasa Corp.); polyclonal rabbit anti-mouse IFN-
(1:2000) (R&D Systems); goat anti-rabbit IgGHRP (Cell Signal-
ing Technology), which was used at 1:2000. Standard curve for
IFN- was generated using purified mouse IFN- (PBL, Inc.).
Quantitative Real-time PCR—Total RNA was harvested
using TRIzol (Invitrogen) followed by reverse transcription
using M-MLV (Invitrogen) and oligo(dT) according to manu-
facturer’s instructions. Q-RT-PCR for murine Tnfa, Il6, and
Il1b was normalized to Gapdh using SYBR-Green (Applied
Biosystems) and the following primer sets: osTnfa, 5-CCCTC-
ACACTCAGATCATCTTCT-3, oaTnf, 5-GCTACGACGT-
GGGCTACAG-3; osIl6, 5-CAACCACGGCCTTCCCTACT-




CCACTGCAA-3. Q-RT-PCR for murine H2-k1, B2m, Tla,
Cd1d, I-Ab, and Nlrc5 was normalized to 18 S RNA using
TaqMan primer/probe sets (Applied Biosystems).
ChIP Assay—Total splenocytes were plated at a cell density
10  106, stimulated with IFN- as indicated (500 units/ml),
but only nonadherent lymphocytes were used for ChIP analyses
as described previously (20, 21). Following cytokine stimula-
tion, cells were cross-linked with 1% formaldehyde for 10 min.
Cross-linkingwas stopped by the addition of 0.125M glycine for
5min. Cells were lysed in SDS lysis buffer andwere sonicated to
generate an average of 500 bp of sheared DNA. Sonicated
lysates were precleared with salmon sperm-coated agarose
beads (Millipore), and then lysates were immunoprecipitated
overnight with 5 g of indicated antibody for H3k27me3
(Abcam), acetylatedH3 (Millipore), H3 (Millipore), and isotype
control antibody (Millipore). Following a 2-h immunoprecipi-
tation with 50 l of salmon sperm-coated agarose beads, sam-
ples were washed with each of the following buffers: low salt
buffer, high salt buffer, LiCl, and Tris-EDTA, and samples were
eluted with SDS elution buffer. Following elution, cross-links
were reversed overnight with 5 M NaCl at 65 °C, and immuno-
precipitated DNA was isolated using phenol:chloroform:iso-
propyl alcohol mix (Invitrogen) as per the manufacturer’s
instructions. Isolated DNA was analyzed by real-time PCR
using primers spanning the proximal promoter region of
H2K1, forward, 5-CCGCGGACGCTGGATA-3, reverse,
5-GGCGATTCGCGACTTCTG-3, and probe, 5-FAM-
AGTCCACGCAGCCCGCAGAACT-TAM-3; I-Ab forward,
5-CTGGATGCTTCCTGAGTTTGG-3, reverse, 5-TGTG-
TTTTACTACAGCTATGTTTTGCA-3, and probe, 5-
FAM-CAATTGGCAAGCTTTGACCCCCAA-TAM-3; and
GAPDH forward, 5-GAGCGGCCCGGAGTCT-3, reverse,
5-GGATTACGGGATGGGTCTGA-3, and probe, 5-FAM-
AAGTATTAGGAACAACCCCACGCGCC-TAM-3. Values
generated from the Q-PCR reaction were normalized to the
total DNA levels (input), and the control IgG levels were sub-
tracted from each immunoprecipitation sample analyzed.
Statistical Analysis and Graphing—Statistical analysis was
done using an on-line program through Vassar College, Vassar-
Stats: Website for Statistical Computation. Graphing was done
using GraphPad Prism.
RESULTS
Production of an Nlrc5/ Mouse Strain by Targeted
Deletion—We produced an Nlrc5/ strain by homologous
targeted replacement of these residues (AKRPFQSYG-
SSPRRKNSKKQQL) from exons 3 and the entire exon 4 with
the Neo cassette (Fig. 1A). Exons 3 and 4 respectively encode a
portion of the CARD-like domain and the entire NBD domain.
The targeting construct was generated with an5-kb region of
the 5 end flanking the targeted deletion and an2.3-kb region
of the 3 end flanking sequence. The targeting vector was con-
firmed by restriction digestion and direct sequencing. The lin-
earized vector was electroporated into IC1 C57BL/6N embry-
onic stem cells, and homologous recombinants were verified by
Southern blot analysis before injection intoBALB/c blastocysts.
The resulting chimeras were mated to female C57BL/6J mice,
and the resulting heterozygotes were crossed to yield homozy-
gousNlrc5/ mice. As indicated in Fig. 1B, a common reverse
primer, a NEO primer, and an NBD primer generated the
expected bands of 650 bp for theWTsamples and 330 bp for the
gene-targeted samples.
Deletion of Nlrc5 Does Not Affect Cytokine Production in
Response to PAMPs andViruses—Asdescribed earlier, previous
work has indicated both positive and negative roles for Nlrc5 in
cytokine production to PAMPs and viruses (11, 13–15). Addi-
tionally, studies in human cells have indicated a role for this
protein in inflammasome activation (16, 17). To determine the
contribution of mouse Nlrc5 to these processes, we first
assessed the production of Tnfa, IL6, and IL-1b mRNA in
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response to LPS and CpG by BMDM. Cytokine mRNA levels
were generally similar betweenWT andNlrc5/ cells with the
only statistically significant differences being less than 1.5-fold
(Fig. 2A). This is reflected at the protein level for TNF and IL6.
For IL-1 production, we additionally tested response to LPS
ATP, or LPSalum, because IL-1 secretion requires two sig-
nals including the activation of pro-IL1 production by LPS
and inflammasome activation by ATP or alum to cause the
post-translational processing of pro-IL1 to mature IL-1 via
caspase-1. Again, deletion of Nlrc5 did not cause a difference.
Parallel experiments were performed with LPS-activated rest-
ing peritoneal macrophages because BMDM have been
expanded in vitro and might generate artificial findings (Fig.
2B). However, no difference was found between WT and
Nlrc5/ peritoneal macrophages. As an additional evaluation,
we also tested for the production of interferon  (IFN-) pro-
tein in response to aDNAvirus, HSV, and anRNAvirus, Sendai
virus. No significant difference in cytokine production was
observed between WT and Nlrc5/ BMDM with the excep-
tion of the high multiplicity of infection of HSV, which showed
a statistically significant, but less than 25% decrease in IFN-
production by Nlrc5/ cells at 24 h (Fig. 2C). Ifnb mRNA
induction by PAMPs including LPS, CpG, and poly(I:C) was
similar between WT and Nlrc5/ BMDM (Fig. 2D). These
results confirm those from a previous study, which did not find
a detectable role for Nlrc5 in cytokine induction by various
PAMPs and microbes (17).
Deletion of Nlrc5 Affects Classical and Nonclassical MHC-I
Expression but Not CD1 andMHC-II Expression—Thework by
Meissner et al. (9) showed that in human cell lines, the gene
knockdown of NLRC5 caused a reduction of MHC-I expres-
sion. Previously, we and others have noted the high levels of
NLRC5 gene expression in immune cells, particularly on T and
B lymphocytes and NK cells (13, 16). To test this in a physio-
logic setting, we used CD45 as a marker for all hematopoietic
cells and assessed MHC-I (H2-Kb and H2-Db) expression by
splenocytes. C57BL/6 lacks theH2-L allele, and thus expression
of this gene cannot be tested in this strain. CD45 hematopoi-
etic cells fromNlrc5/ mice showed a significant reduction of
both H-2K and H-2D expression. Among CD45 cells, one
population has amore dramatic loss ofMHC-I than another, as
revealed by the two peaks of MHC-I staining in the Nlrc5/
sample (Fig. 3A). A further separation of the cells shows that
splenic T cells showed the most dramatic loss of MHC-I fol-
lowed by NK cells, B lymphocytes, dendritic cells (CD11bint/
CD11c), and macrophages (CD11b, CD11clo). To further
assess whether this is reflected at the transcriptional level, we
sorted different populations, isolated RNA, and tested for the
expression of a classical MHC-I gene (H-2k1), the common
partner ofMHC-I (B2m), and a nonclassicalMHC-I gene (Tla).
All three were largely reduced in the lymphoid lineage (Fig. 3B).
In contrast, Cd1d2, which encodes the CD1 protein that pres-
ents lipids and is not generally co-regulated withMHC-I, is not
altered in Nlrc5/ cells. Finally, Nlrc5 deletion did not affect
MHC-II gene expression represented by I-A in B cells, but it did
cause a slight, but significant, decrease inMHC-II expression in
CD11b cells. Decreased MHC-I expression in the absence of
Nlrc5 is not restricted to the spleen as CD4CD8 (double
negative), aswell asCD4 andCD8 single positive thymocytes, in
Nlrc5/ mice all have reducedMHC-I (Fig. 3C). We observed
similar MHC-I expression betweenWT and Nlrc5/ DP thy-
mocytes, which may reflect lowNlrc5mRNA expression in the
WT population (Fig. 3, C and D).
NLRC5 Does Not Alter the Extent of IFN-induced MHC-I
Expression—Prior work with CIITA indicates that this protein
regulates both basal and inducible expression of MHC-II (2,
22). To determine whether Nlrc5 has a parallel function, we
assessed the induced expression of MHC-I by IFN-, a known
inducer of MHC-I. An analysis of T and B cells indicates that
although the basal level of MHC-I is reduced inNlrc5/ cells,
the induction of MHC-I by IFN- in both populations
remained intact (Fig. 4A). These data are consistent with
MHC-I mRNA analysis showing similar relative increases in
H2-k1messagewith IFN- treatment; however, theMHC-I lev-
els in Nlrc5/ cells are consistently reduced when compared
with WT controls (Fig. 4B). Additionally, IFN--induced
MHC-I expression occurs on Nlrc5/ and Ciita/ BMDM
(Fig. 4C). IFN--induced MHC-II surface expression was nor-
mal on Nlrc5/ BMDM but reduced on Ciita/ cells as
expected (Fig. 4D). The decreased expression ofMHC-I but not
MHC-II in response to IFN- treatment is also reflected at the
mRNA level in Nlrc5/ cells (Fig. 4E). These results indicate
that unlike CIITA, which is crucial for both basal and IFN--
FIGURE 1. Targeted ablation of the Nlrc5 NBD coding region. A, targeting
construct with 5-kb region of homology in the 5 end (targeting the NBD
coding region and upstream exon) and 2.3-kb homology 3 to the NBD
coding region. Primers for duplex PCR genotype analysis are indicated: P1, WT
Nlrc5 NBD-specific primer; P2, neomycin-specific primer; P3, common primer.
B, PCR products from WT and Nlrc5/ genomic DNA using primers described
in A. Lane 1, DNA standard (Std); lanes 2– 4, tail genomic DNA from three
Nlrc5/ mice; lanes 5–7, tail genomic DNA from three WT mice.
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inducedMHC-II expression, Nlrc5 does not affect the extent of
IFN--induced up-regulation ofMHC-I, but rather is necessary
for basal constitutiveMHC-I expression, which then affects the
final amount of MHC-I expressed by cells after IFN-
stimulation.
CIITA Does Not Regulate MHC-I Expression in Mouse B
Lymphocytes—The earlier experiments indicate that the effect
ofNlrc5 deletion on classicalH-2K and B2m expression is most
dramatic in T cells and less so in B cells (Fig. 3, A and B). Prior
work has shown that CIITA can regulate MHC-I in human
cells, and furthermore, CIITA is highly expressed by B cells (6,
7). Thus one possibility is that CIITA and Nlrc5 both regulate
MHC-I expression in B cells, whereas CIITA expression does
not affect MHC-I expression by T cells because the level of
CIITA is negligible in mouse T cells. An assessment of
Nlrc5/, Ciita/, and WT cells indicates that although
Nlrc5/T andB cells express lessH-2K antigen, H-2K expres-
sion by Ciita/ T and B cells is similar to wild type (Fig. 5A).
This indicates thatCiita deletion does not result in a detectable
loss of MHC-I expression by B cells in the murine system. We
also do not detect a decrease inMHC-II expressionNlrc5/ B
cells (Fig. 5B), suggesting thatNlrc5 control ofMHCexpression
is restricted to MHC-I.
Nlrc5 Is Required for the Removal of the Silencing Mark
H3K27me3 from the MHC-I Proximal Promoter—Although
others have noted the regulation ofMHC-I byNlrc5, themech-
anism has not been explored. Gene expression occurs within
the highly ordered context of chromatin, and open chromatin
structure is required for transcription initiation. To determine
the histone modification of the MHC-I promoter, levels of
acetylation and trimethylation of lysine 27 on histone H3 were
assessed in lymphocyte-enriched splenocytic populations and
BMDM. After IFN- treatment,WT cells progressively lost the
gene silencing H3K27me3 modification at the MHC-I pro-
moter,H-2K1, which agrees with IFN- induction of this gene.
By contrast, Nlrc5/ cells did not show reduced H3K27me3
modification and even exhibited increased methylated state at
the 4-h time point (Fig. 6A). Both WT and Nlrc5/ cells
showed similar acetylation of H3 at theMHC-I promoter upon
IFN- treatment, which is associated with increased chromatin
accessibility and gene transcription (Fig. 6B). The unabated and
increased H3K27me3 in Nlrc5/ cells was specific to the
MHC-I promoter as normal demethylation and acetylation
were generally observed for the MHC-II (Fig. 6, C and D) and
GAPDH (Fig. 6,E and F) proximal promoters upon IFN- treat-
ment. An exception is the increased H2K27me3 at I-Ab pro-
moter in the BMDM  IFN- group at the 4-h time point,
which needs to be explored further in the future. Increased
H3K27me3 at the MHC-I promoter region is not due to
increased histone levels as control assays demonstrated no sig-
nificant changes in total histone H3 associated with MHC-I or
MHC-II (Fig. 6, G and H). These data are consistent with a
mechanism in which the MHC-I promoter in Nlrc5/ cells
becomes partially accessible in response to IFN- through
FIGURE 2. Cytokine expression by WT and Nlrc5/ macrophages in response to PAMP and DAMP stimulation and viral infection. A and B, Q-RT-PCR for
mRNA (top) and ELISA for protein secretion (bottom) of indicated cytokines by BMDM (A) and peritoneal macrophages (B) 8 h after stimulation; data are graphed
as -fold change over WT untreated control (UT). Rel. expression, relative expression. C, ELISA for IFN- secretion by BMDM infected with HSV (left) or Sendai Virus
(SeV) (right) at 8 and 24 h after infection. D, Q-RT-PCR for Ifnb mRNA expression in BMDM 8 h after PAMP stimulation. Data in A, B, and D are representative of
three independent experiments. Data in C are representative of two independent experiments. Q-RT-PCR data are normalized to 18 S RNA expression. Error
bars  S.E.; statistical analysis by two-tailed Student’s t test, *, p  0.05, **, p  0.01.
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increased H3 acetylation; however, the inability to reach WT
levels ofMHC-I expression after IFN- stimulation is likely due
to an inability of Nlrc5/ cells to remove H3K27me3 at the
MHC-I promoter.
Detection of a 3-End Transcript That Originates from Nlrc5
in WT and Nlrc5/ Mice—While this manuscript was under
review, Tong et al. (23) reported that deletion of Nlrc5 by tar-
geting the C-terminal LRR1 also decreased MHC-I expression,
but additionally increased NF-B-dependent cytokine and
type-I interferon production in response to various stimuli.Our
studies did not indicate an NF-B or a type-I interferon pheno-
type, and we considered the possibility that our Nlrc5 knock-
out strategy (which targeted the nucleotide-binding domain)
may allow for expression of Nlrc5 variant proteins that fail to
induce normalMHC-I expression, but are sufficient to dampen
NF-B and type-I interferon responses. We examined Nlrc5
mRNA expression in several resting and stimulated cell subsets
using a primer/probe set that anneals to the 3 end of the mRNA
(Fig. 7A, Primer/Probe). We found equivalent, if not increased,
levelsofNlrc5mRNAtranscriptscontaining thisendof themRNA
in the Nlrc5/ splenic populations when compared with WT
(Fig. 7B). Stimulation of total splenocytes or BMDM with IFN-
(Fig. 7,C andD) or stimulation of BMDMwith Toll-like receptor
(TLR) agonists (Fig. 7E) resulted in up-regulation of this 3 end
transcript equal to, or greater than, WT control samples. These
data suggest that Nlrc5 may be autoinhibitory at the mRNA level
and leaves open the possibility that alternative splice forms of
Nlrc5 that contain the 3 end, althoughunable tomaintainnormal
MHC-I expression, could be sufficient for normal regulation of
NF-B and type-I interferon responses.
FIGURE 3. Flow cytometric and Q-RT-PCR analysis of MHC expression in WT and Nlrc5/ mice. A, surface H2-Kb and H2-Kd expression in WT (black) and
Nlrc5/ (blue) splenocyte populations. B, Q-RT-PCR for H2-k1, B2m, Tla, Cd1d2, and I-Ab mRNA expression in sorted splenic B, T, and NK populations. Rel.
expression, relative expression. C, flow cytometric analysis of H2-Kb expression in WT (black) and Nlrc5/ (blue) thymocyte populations. % of max, percentage
of maximum; DN, double negative; DP, double positive. D, Q-RT-PCR for Nlrc5 mRNA expression in sorted WT thymocyte populations. Flow cytometric data in
A and C are representative of five experiments; Q-RT-PCR data are combined from least two independent experiments and normalized to 18 S RNA expression.
Error bars  S.E. Statistical analysis by two-tailed Student’s t test, *, p  0.05, **, p  0.01.
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DISCUSSION
This study describes an assessment of the physiologic func-
tion ofNLRs by studying a targeted deletion of theNBDdomain
of Nlrc5. The NBD domain for most NLRs contains Walker A
and B motifs, which are conserved among ATP-binding pro-
teins. A study ofNlrc5 has shown thatmutation of theWalkerA
and B motifs destroyed the ability of this protein to induce
MHC-I transcription and nuclear translocation (9). Interest-
ingly, previous data similarly showed the critical role of the
Walker A and B motifs within CIITA in mediating nuclear
translocation as well as MHC-II transactivation function (24–
26). Others have shown that bacterially expressed partially
purified NBD domain of NLRC4/ipaf binds ATP (27). Nucleo-
tide binding by purified, full-length NLRP3 and NLRP12 was
previously reported by our group with studies showing that
bothNLRs bindATP and dATP but not CTP, GTP, or UTP and
exhibit ATPase activity (28, 29). Others have shown that similar
mutations of NOD2 also led to the loss of function (30). Thus
theNBD domain plays important functions amongmanyNLRs
examined.
The gene expression pattern ofNlrc5 indicates that it is high-
est in T lymphocytes, NK cells, and B cells. Indeed it has the
most profound effect on MHC-I expression by T lymphocytes
andNK cells, whereas its effect onMHC-I expression by B cells
is less than the former two cell types. One can speculate that
perhaps B cells express otherMHC-I-regulatingNLRs.Ahighly
FIGURE 4. Flow cytometric and Q-RT-PCR analysis of H2-Kb expression by WT and Nlrc5/ splenocytes or BMDM in response to INF- treatment. A,
surface H2-Kb expression on in vitro cultured splenocytes, untreated (gray filled) or INF--treated for 24 h (black). % of max, percentage of maximum; UT,
untreated control. B, Q-RT-PCR for H2-k1 mRNA expression by in vitro cultured splenocytes from WT or Nlrc5/ mice at the indicated time points after IFN-
treatment. C, surface H2-Kb expression on BMDM, untreated (gray filled) or INF--treated at 24 h (black). D, surface I-Ab expression on BMDM, untreated (gray
filled) or INF--treated at 24 h (black). Numbers under the histogram in C and D are mean fluorescence intensities. E, Q-RT-PCR for H2-k1 and I-Ab mRNA
expression in WT or Nlrc5/ BMDM treated with IFN-. Q-RT-PCR data are combined from at least two independent experiments and normalized to 18 S RNA
expression. Error bars  S.E. Data are representative of two independent experiments. Statistical analysis by two-tailed Student’s t test, *, p  0.05, **, p  0.01.
Rel. expression, relative expression.
FIGURE 5. Flow cytometric analysis of MHC-I and MHC-II surface expres-
sion by WT, Nlrc5/, and Ciita/ mice. A, surface H2-Kb expression in WT
(red), Nlrc5/ (blue), and Ciita/ (green dashed) splenic B and T cells. Gray,
isotype control. % of max, percentage of maximum. B, flow cytometric analy-
sis of I-Ab expression in WT (red), Nlrc5/ (blue), and Ciita/ (green dashed) B
cells. Data are representative of three independent experiments.
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FIGURE 6. Levels of H3K27me3 and acetylated H3 at MHC-I (H-2K1) and MHC-II (I-Ab) proximal promoters in WT and Nlrc5/ lymphocyte-enriched
splenocytes and BMDM. ChIP assays were carried out in cells stimulated as indicated with IFN-. Lysates were immunoprecipitated with control antibody,
antibody to H3K27me3 (A, C, E, and F), acetylated H3 (B, D, E, and F), or total H3 (G and H), and associated DNA was isolated and analyzed via Q-PCR using primers
spanning the proximal promoter region of H2-K1 (A, B, and G), I-Ab (C, D, and H), and Gapdh (E and F). Values for immunoprecipitations represent the mean 
S.E. of three independent experiments. UT, untreated control.
FIGURE 7. Q-RT-PCR for 3 end of Nlrc5 transcript in splenocytes and BMDM from WT or Nlrc5/ mice. A, schematic depicting the full-length Nlrc5
transcript including the AUG start, the NBD encoded by exon 4, and the 3 Q-RT-PCR primer/probe set spanning exons 48 – 49 (dashed line). B–D, Q-RT-PCR with
primer/probe set depicted in A. B, sorted resting splenocytes. C, total splenocytes cultured in vitro with IFN- for the indicated times. D, BMDM treated with
IFN- for the indicated times. E. BMDM 8 h after PAMP stimulation. Data in B are combined from at least two independent experiments, and data in C–E are
representative of at least two independent experiments. Q-RT-PCR data are normalized to 18 S RNA expression. Error bars  S.E. Rel. expression, relative
expression; UT, untreated control.
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probable candidate is CIITA, which has been found by many
laboratories to update MHC-I in human cells (6, 7). The initial
studies documenting the role of CIITA in MHC-I regulation
were considered physiologically relevant as they relied on
mutant cell lines with defective CIITA, as opposed to artificial
overexpression systems. The physiologic relevance of CIITA in
murineMHC-I is readdressed in this study, but we failed to find
its role in the regulation of mouse MHC-I. In addition, our
study also shows that although constitutive MHC-I expression
is reduced in Nlrc5/ cells, the extent of IFN--induced
MHC-I expression remained unaltered despite the overall
reduction inMHC-I expressionwhen comparedwithWTcells.
Finally, our study indicates that Nlrc5 regulates the transcrip-
tion of both classical MHC-I as well as the nonclassical Tla
gene. Thus Nlrc5 likely controls MHC-I through conserved
motifs found in classical and nonclassical MHC-I promoter.
Additionally, our data hint at the possibility that Nlrc5 has a
slight effect on MHC-II expression. For example, I-Ab mRNA
byCD11b cells is slightly reduced in the absence of Nlrc5, and
H3K27me3 modification of I-Ab promoter revealed a different
kinetics in control versus Nlrc5/ cells. A recent study showed
that NLRC5 can associate with RFX, a DNA-binding protein
that regulatesMHC-II (31). Hence additional work is necessary
to assess whether Nlrc5 cross-regulates MHC-II under some
conditions.
The above data suggest that unlikeCIITA,which is necessary
for promoter loading of multiple transcription factors and his-
tone modification factors including histone acetylases and
methylases atMHC-II promoters (32), Nlrc5might play amore
defined role in its regulation of MHC-I. Consistent with this
working model, the data show that although Nlrc5 is an impor-
tant regulator of proper chromatin dynamics at MHC-I pro-
moter, the effect is rather specific. Our study demonstrates that
decreased expression of MHC-I in Nlrc5/ knock-out cells is
associated with increased levels of H3K27me3 but normal his-
tone 3 acetylation. These observations underscore the domi-
nance of H3K27me3 in down-regulating the transcriptional
status of MHC-I chromatin in the absence of Nlrc5.
Aside from the regulation of MHC-I, our study has not been
able to identify other functions of Nlrc5 that have been identi-
fied by previous studies, including our own, which showed that
two interference RNAs targeting Nlrc5 caused a drastic reduc-
tion of inflammasome activation by an array of stimuli in
human cell lines and primary peripheral blood mononuclear
cells (16). Although it is difficult to reconcile the opposing func-
tions found forNlrc5 in cytokine induction by PAMPs reported
in the literature, there are a number of explanations for the
inability of Nlrc5/ cells to confirm previous findings. 1) For
the previous studies performed in human cells, it is possible
that there are species-specific differences, which are ample
among the other NLRs. For example, NLRP1 from humans and
mice serve similar functions in inflammasome activation, but
the former is responsive tomuramyl dipeptide (MDP), whereas
the latter is activated by Bacillus anthracis lethal toxin (33). 2)
Along this same line, it is possible that there are gene redun-
dancies in mice that are not found in humans. Mice have 38
NLR genes, whereas humans only have 22 NLR genes. As an
example, whereas humans have one copy of the NAIP gene,
mice have six copies of the gene (34, 35). 3) It is possible that the
function of the Nlrc5 is cell type- and stimulus-dependent, and
we have not identified the correct stimulus in the appropriate
cell types. However, the reduction of MHC-I in Nlrc5/ cells
was observed in all cell types surveyed, so the ability of Nlrc5 to
regulate MHC-I is not cell-specific, although the degree in
whichNlrc5 controlsMHC-I does varywith the cell type. 4) It is
possible that deleting the NBD domain is not sufficient to elim-
inate all functions of Nlrc5 and that the gene deletion might
have resulted in a functional protein without NBD. At the time
of this submission, another group used a different gene-target-
ing strategy to show that Nlrc5 deletion resulted in a loss of
MHC-I gene expression (36). During the review of this manu-
script, two other groups have also shown a role for Nlrc5 in
MHC-I expression, but one found an additional role for Nlrc5
in dampening cytokine response (23), whereas another found a
role for this gene in inflammasome activation (37). As the var-
ious groups used different gene deletion strategies, it is possible
that residual transcripts in the different gene deletion strains
might be able to regulate functions other than MHC-I expres-
sion. The detection of a 3 end transcript that originates from
Nlrc5 in the strain that we produced suggests that this possibil-
ity deserves a further investigation.
The above caveats do not take away from the definitive
results that support the findings of Meissner et al. (9) observed
in cell lines. Together, these results indicate thatNlrc5 is a bona
fideMHC-I gene transcriptional regulator. It is interesting that
CIITA andNlrc5 serve similar functions, the humanCIITA and
Nlrc5 are on the same chromosome (38), and their NBD and
leucine-rich repeat (LRR) are most closely related on a phylo-
genetic tree (11). Since the discovery of the NLR family, some
have argued that CIITA does not belong to this family because
it is the only NLR protein with a transcriptional function. The
discovery of Nlrc5 inMHC-I gene transcription clearly negates
this concern and indicates that CIITA has at least one closely
related relative with similar function. Thus CIITA and Nlrc5
represent bridges between innate immune genes and regulators
of MHC that play pivotal roles in adaptive immunity.
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